Table 1.

Primary NSCLC patient information

Primary cells	Gender	Age (years)	Pathology	Immunohistochemistry	EGFR mutation
LS-1#	Male	58	Metastatic lung adenocarcinoma	TTF1[+], Napsin A[+], CK7[+], CK20[+], GFAP[−], Ki-67[+,15%-20%]	EGFR (wt)
LS-2#	Female	52	Peripulmonary moderately to poorly differentiated lung adenocarcinoma	CK7[+], CK20[−], CK5/6[−], P63[−], Napsin A[+], TTF1[+], ALK[0], Ki-67[+,2%-5%]	EGFR (20 lns)
LS-3#	Male	71	Invasive lung adenocarcinoma	ROS1(−), c-Met(++,80%), CK5/6(−), CK7(+), P40(−), P63(−), TTF1(+), Napsin A(+)	EGFR (wt)
LS-4#	Male	71	Invasive lung adenocarcinoma	CK20(−), CDX-2(−), c-Met(+,10%), CK5/6(−), ROS1(+,5%), CK7(−), P40(−), P63(−), TTF1(+), Napsin A(+), ALK(D5F3)(−)	EGFR (wt)

EGFR, epidermal growth factor receptor; wt, wild-type.